Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/multiple-sclerosis-treatment-with-fingolimod-profile-of-non-ZLjYgCjva0
References (130)
-
OJ Coppes, I Gutierrez, AT Reder, S Ksiazek, J Bernard (2013)
Severe early bilateral macular edema following fingolimod therapyMult Scler Relat Disord, 2
-
EW Radue (2012)
1259Arch Neurol, 69
-
A Schwarz (2010)
2022Neurology, 74
-
L Liu (2012)
134636Case Rep Med, 2012
-
N Ueda (2015)
135BMC Ophthalmol, 15
-
EY Chen (2012)
2420Hepatology, 56
-
MH Harirchian, A Taalimi, B Siroos (2015)
Emerging tumefactive MS after switching therapy from interferon beta to fingolimod: a case reportMult Scler Relat Disord, 4
-
T Tully, A Barkley, E Silber (2015)
Kaposi sarcoma in a patient with relapsing-remitting multiple sclerosis receiving fingolimodNeurology, 84
-
L Liu, F Cuthbertson (2012)
Early bilateral cystoid macular edema secondary to fingolimod in multiple sclerosisCase Rep Med, 2012
-
H Seto, M Nishimura, K Minamiji, S Miyoshi, H Mori, K Kanazawa, H Yasuda (2016)
Disseminated Cryptococcosis in a 63-year-old patient with multiple sclerosis treated with fingolimodIntern Med, 55
-
MA Hellmann, N Lev, I Lotan, R Mosberg-Galili, E Inbar, J Luckman, S Fichman-Horn, M Yakimov, I Steiner (2014)
Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapyJ Neurol Sci, 344
-
YD Fragoso, JB Brooks (2015)
A specific vaccine to protect patients with multiple sclerosis from herpes zosterArq Neuropsiquiatr, 73
-
T Tully (2015)
1999Neurology, 84
-
F Visser (2012)
2000Neurology, 79
-
J Flores (2015)
272J Neurol Sci, 348
-
BO Khatri (2016)
Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidenceTher Adv Neurol Disord, 9
-
R Pul, A Osmanovic, H Schmalstieg, A Pielen, K Pars, P Schwenkenbecher, KW Sühs, Ö Yildiz, B Frank, M Stangel, T Skripuletz (2016)
Fingolimod associated bilateral cystoid macular edema-wait and see?Int J Mol Sci, 17
-
JA Rossum, EE Looysen, JM Daniels, J Killestein (2014)
Fingolimod-induced asthma deterioration in a patient with relapsing-remitting multiple sclerosisMult Scler, 20
-
L Mantia, I Tramacere, B Firwana, I Pacchetti, R Palumbo, G Filippini (2016)
Fingolimod for relapsing-remitting multiple sclerosisCochrane Database Syst Rev, 4
-
AK Forrestel (2016)
355JAMA Neurol, 73
-
BO Khatri (2016)
130Ther Adv Neurol Disord, 9
-
G Pilz (2013)
1654Neurology, 81
-
H Hagiya (2016)
830J Infect Chemother, 22
-
C Lundblad, H Axelberg, PO Grände (2013)
Treatment with the sphingosine-1phosphate analogue FTY720 reduces loss of plasma volume during experimental sepsis in the ratActa Anaesthesiol Scand, 57
-
JR Berger (2017)
59Mult Scler Relat Disord., 12
-
L Kappos (2010)
387N Engl J Med, 362
-
M Tölle (2005)
913Circ Res, 29
-
A Uccelli, F Ginocchio, GL Mancardi, M Bassetti (2011)
Primary varicella zoster infection associated with fingolimod treatmentNeurology., 76
-
M Kraemer (2015)
1473Mult Scler, 21
-
G Pilz, A Harrer, P Wipfler, P Wipfler, K Oppermann, J Sellner, F Fazekas, E Trinka, J Kraus (2013)
Tumefactive MS lesions under fingolimod: a case report and literature reviewNeurology, 81
-
S Boangher, S Goffette, V Pesch, P Mespouille (2016)
Early relapse with tumefactive MS lesion upon initiation of fingolimod therapyActa Neurol Belg, 116
-
A Marrone, E Signoriello, G Alfieri, L Dalla Mora, L Rinaldi, I Rainone, LE Adinolfi, G Lus (2014)
Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatmentInfez Med, 22
-
K Ikumi, T Ando, H Katano, M Katsuno, Y Sakai, M Yoshida, T Saida, H Kimura, G Sobue (2016)
HSV-2-related hemophagocytic lymphohistiocytosis in a fingolimod-treated patient with MSNeurol Neuroimmunol Neuroinflamm., 3
-
AK Artemiadis, G Nikolaou, D Kolokythopoulos, N Tegos, A Terentiou, N Triantafyllou, I Papanastasiou (2015)
Visceral leishmaniasis infection in a fingolimod-treated multiple sclerosis patientMult Scler, 21
-
YD Fragoso, HK Sato (2016)
Catastrophic magnetic resonance images in the central nervous system of patients undergoing treatment with fingolimodCNS Neurosci Ther, 22
-
A Bianco (2016)
11Mult Scler Relat Disord, 9
-
AK Forrestel, BG Modi, S Longworth, MB Wilck, RG Micheletti (2016)
Primary cutaneous Cryptococcus in a patient with multiple sclerosis treated with fingolimodJAMA Neurol, 73
-
NP Issa, A Hentati (2015)
VZV encephalitis that developed in an immunized patient during fingolimod therapyNeurology, 84
-
H Lindå (2015)
39Front Neurol, 6
-
MM Kawiorski (2015)
138Enferm Infecc Microbiol Clin, 33
-
MO Kinney (2013)
403Neurology, 81
-
YD Fragoso, T Adoni, S Gomes, MV Goncalves, AP Matta, MF Mendes, F Siquineli (2015)
Persistent headache in patients with multiple sclerosis starting treatment with fingolimodHeadache, 55
-
S Faissner (2015)
233Ther Adv Neurol Disord, 8
-
A Meissner, V Limmroth (2016)
Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MSMult Scler Relat Disord., 8
-
AR Afshar (2013)
103JAMA Ophthalmol, 131
-
V Behle, M Wobser, M Goebeler, J Stoevesandt (2016)
Extensive molluscum contagiosum virus infection in a young adult receiving fingolimodMult Scler, 22
-
M Russo, C Guarneri, E Mazzon, E Sessa, P Bramanti, RS Calabrò (2015)
Fingolimod-associated peripheral vascular adverse effectsMayo Clin Proc, 90
-
MO Kinney, G McDonnell (2013)
Tumefactive multiple sclerosis lesions under fingolimod treatmentNeurology, 81
-
YD Fragoso (2016)
650Arq Neuropsiquiatr, 74
-
EY Chen, K Baum, W Collins, A Löve, M Merz, S Olafsson, ES Björnsson, WM Lee (2012)
Hepatitis E masquerading as drug-induced liver injuryHepatology, 56
-
S Jander, B Turowski, BC Kieseier, HP Hartung (2012)
Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimodMult Scler, 18
-
MT Bhatti, SM Freedman, TH Mahmoud (2013)
Fingolimod therapy and macular hemorrhageJ Neuroophthalmol, 33
-
LJ Spijkers, AE Alewijnse, SL Peters (2012)
FTY720 (fingolimod) increases vascular tone and blood pressure in spontaneously hypertensive rats via inhibition of sphingosine kinaseBr J Pharmacol, 166
-
E Grebenciucova (2016)
158Mult Scler Relat Disord, 9
-
MD Ward, DE Jones, MD Goldman (2014)
Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosisExpert Opin Drug Saf., 13
-
A Uccelli (2011)
1023Neurology., 76
-
H Seto (2016)
3383Intern Med, 55
-
H Hagiya, H Yoshida, M Shimizu, D Motooka, S Nakamura, T Iida, N Yamamoto, Y Akeda, K Tomono (2016)
Herpes zoster laryngitis in a patient treated with fingolimodJ Infect Chemother, 22
-
JA Cohen, F Barkhof, G Comi, HP Hartung, BO Khatri, X Montalban, J Pelletier, R Capra, P Gallo, G Izquierdo, K Tiel-Wilck, A Vera, J Jin, T Stites, S Wu, S Aradhye, L Kappos (2010)
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosisN Engl J Med, 362
-
T Sanchez (2003)
47281J Biol Chem, 21
-
G Karlsson, G Francis, G Koren, P Heining, X Zhang, JA Cohen, L Kappos, W Collins (2014)
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosisNeurology, 82
-
LJ Scott (2011)
Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosisCNS Drugs, 25
-
V Li, J Kane, HH Chan, AJ Hall, H Butzkueven (2014)
Continuing fingolimod after development of macular edema: a case reportNeurol Neuroimmunol Neuroinflamm, 1
-
MA Hellmann (2014)
193J Neurol Sci, 344
-
JN Ratchford, K Costello, DS Reich, PA Calabresi (2012)
Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimodNeurology, 79
-
J Flores, Y Rito, G Torres, H Jung, I Treviño-Frenk, T Corona (2015)
Hypothyroidism in multiple sclerosis patient during fingolimod treatmentJ Neurol Sci, 348
-
A Schwarz, M Korporal, W Hosch, R Max, B Wildemann (2010)
Critical vasospasm during fingolimod (FTY720) treatment in a patient with multiple sclerosisNeurology, 74
-
L Mantia La (2016)
CD009371Cochrane Database Syst Rev, 4
-
MM Kawiorski, E Viedma-Guiard, L Costa-Frossard, I Corral (2015)
Polydermatomal perineal and gluteal herpes zoster infection in a patient on fingolimod treatmentEnferm Infecc Microbiol Clin, 33
-
A Marrone (2014)
331Infez Med, 22
-
RG Beran, Y Hegazi, RS Schwartz, DJ Cordato (2013)
Rebound exacerbation multiple sclerosis following cessation of oral treatmentMult Scler Relat Disord., 2
-
L Achtnichts, O Obreja, A Conen, CA Fux, K Nedeltchev (2015)
Cryptococcal meningoencephalitis in a patient with multiple sclerosis treated with fingolimodJAMA Neurol, 72
-
P Mandal, A Gupta, W Fusi-Rubiano, PA Keane, Y Yang (2016)
Fingolimod: therapeutic mechanisms and ocular adverse effectsEye (Lond)
-
AM Arvin, JS Wolinsky, L Kappos, MI Morris, AT Reder, C Tornatore, A Gershon, M Gershon, MJ Levin, M Bezuidenhoudt, N Putzki (2015)
Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for managementJAMA Neurol, 72
-
YD Fragoso (2015)
578Headache, 55
-
JA Cohen (2010)
402N Engl J Med, 362
-
F Leypoldt, A Münchau, F Moeller, M Bester, C Gerloff, C Heesen (2009)
Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case reportNeurology, 72
-
NP Issa (2015)
99Neurology, 84
-
H Lindå, A Heijne (2015)
A case of posterior reversible encephalopathy syndrome associated with Gilenya(®) (fingolimod) treatment for multiple sclerosisFront Neurol, 6
-
YD Fragoso (2015)
370Arq Neuropsiquiatr, 73
-
L Achtnichts (2015)
1203JAMA Neurol, 72
-
MD Ward (2014)
989Expert Opin Drug Saf., 13
-
R Gallego-Pinazo, E España-Gregori, B Casanova, D Pardo-López, M Diaz-Llopis (2011)
Branch retinal vein occlusion during fingolimod treatment in a patient with multiple sclerosisJ Neuroophthalmol, 31
-
N Jain (2012)
672Neurology, 78
-
V Behle (2016)
969Mult Scler, 22
-
JA Rossum van (2014)
1792Mult Scler, 20
-
JN Ratchford (2012)
2002Neurology, 79
-
M Russo (2015)
1424Mayo Clin Proc, 90
-
A Tagawa, T Ogawa, S Tetsuka, M Otsuka, R Hashimoto, H Kato, K Ando, H Tanabe (2016)
Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosisMult Scler Relat Disord, 9
-
MH Harirchian (2015)
400Mult Scler Relat Disord, 4
-
E Grebenciucova, AT Reder, JT Bernard (2016)
Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: a case report and review of literatureMult Scler Relat Disord, 9
-
MT Bhatti (2013)
370J Neuroophthalmol, 33
-
TV Gyang (2016)
1843Neurology., 86
-
A Bianco, AK Patanella, V Nociti, C Fino, M Lucchini, FL Savio, PM Rossini, M Mirabella (2016)
Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatmentMult Scler Relat Disord, 9
-
N Ueda, K Saida (2015)
Retinal haemorrhages following fingolimod treatment for multiple sclerosis; a case reportBMC Ophthalmol, 15
-
JR Berger (2017)
Classifying PML risk with disease modifying therapiesMult Scler Relat Disord., 12
-
S Faissner, R Hoepner, C Lukas, A Chan, R Gold, G Ellrichmann (2015)
Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatmentTher Adv Neurol Disord, 8
-
S Belliston (2016)
1Int J Neurosci, 23
-
LJ Scott (2011)
673CNS Drugs, 25
-
S Belliston, J Sundararajan, N Hammond, K Newell, S Lynch (2016)
Reversible cerebral vasoconstriction syndrome in association with fingolimod useInt J Neurosci, 23
-
C Zecca (2014)
987Patient Prefer Adherence, 8
-
TV Gyang, J Hamel, AD Goodman, RA Gross, L Samkoff (2016)
Fingolimod-associated PML in a patient with prior immunosuppressionNeurology., 86
-
M Kraemer, R Weber, M Herold, P Berlit (2015)
Reversible cerebral vasoconstriction syndrome associated with fingolimod treatment in relapsing-remitting multiple sclerosis three months after childbirthMult Scler, 21
-
PA Calabresi, EW Radue, D Goodin, D Jeffery, KW Rammohan, AT Reder, T Vollmer, MA Agius, L Kappos, T Stites, B Li, L Cappiello, P Rosenstiel, FD Lublin (2014)
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trialLancet Neurol., 13
-
C Zecca, M Caporro, S Györik, C Gobbi (2014)
Life-threatening asthma attack during prolonged fingolimod treatment: case reportPatient Prefer Adherence, 8
-
F Leypoldt (2009)
1022Neurology, 72
-
YD Fragoso (2016)
633CNS Neurosci Ther, 22
-
AK Artemiadis (2015)
795Mult Scler, 21
-
S Jander (2012)
1650Mult Scler, 18
-
C Lundblad (2013)
713Acta Anaesthesiol Scand, 57
-
YD Fragoso, SV Alves-Leon, J Becker, JB Brooks, EC Correa, A Damasceno, PD Gama, RA Gama, AP Matta, EP Maciel, TC Winckler (2016)
Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosisArq Neuropsiquiatr, 74
-
V Li (2014)
e13Neurol Neuroimmunol Neuroinflamm, 1
-
L Kappos, E-W Radue, P O’Connor, C Polman, R Hohlfeld, P Calabresi, K Selmaj, C Agoropoulou, M Leyk, L Zhang-Auberson, P Burtin (2010)
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisN Engl J Med, 362
-
OJ Coppes (2013)
256Mult Scler Relat Disord, 2
-
D Huang (2015)
Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimodNeurology, 85
-
R Alroughani, A Almulla, S Lamdhade, A Thussu (2014)
Multiple sclerosis reactivation postfingolimod cessation: is it IRIS?BMJ Case Rep
-
A Tagawa (2016)
155Mult Scler Relat Disord, 9
-
AR Afshar, JK Fernandes, RD Patel, SM Ksiazek, VS Sheth, AT Reder, SM Hariprasad (2013)
Cystoid macular edema associated with fingolimod use for multiple sclerosisJAMA Ophthalmol, 131
-
A Meissner (2016)
19Mult Scler Relat Disord., 8
-
B Jones (2014)
Multiple sclerosis: study reinforces need for contraception in women taking fingolimodNat Rev Neurol., 10
-
EW Radue, P O’Connor, CH Polman, R Hohlfeld, P Calabresi, K Selmaj, N Mueller-Lenke, C Agoropoulou, F Holdbrook, A Vera, L Zhang-Auberson, G Francis, P Burtin, L Kappos (2012)
Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosisArch Neurol, 69
-
F Lublin, DH Miller, MS Freedman, BA Cree, JS Wolinsky, H Weiner, C Lubetzki, HP Hartung, X Montalban, BM Uitdehaag, M Merschhemke, B Li, N Putzki, FC Liu, DA Häring, L Kappos (2016)
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trialLancet, 387
-
T Sanchez, T Estrada-Hernandez, JH Paik, MT Wu, K Venkataraman, V Brinkmann, K Claffey, T Hla (2003)
Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeabilityJ Biol Chem, 21
-
AM Arvin (2015)
31JAMA Neurol, 72
-
S Boangher (2016)
95Acta Neurol Belg, 116
-
R Pul (2016)
12Int J Mol Sci, 17
-
N Jain, MT Bhatti (2012)
Fingolimod-associated macular edema: incidence, detection, and managementNeurology, 78
-
D Huang (2015)
1001Neurology, 85
-
R Gallego-Pinazo (2011)
292J Neuroophthalmol, 31
-
M Tölle, B Levkau, P Keul, V Brinkmann, G Giebing, G Schönfelder, M Schäfers, Lipinski K Wnuck, J Jankowski, V Jankowski, J Chun, W Zidek, M Giet (2005)
Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3Circ Res, 29
- Publisher
- Springer Journals
- Copyright
- Copyright © 2017 by Belgian Neurological Society
- Subject
- Biomedicine; Neurosciences; Neurology; Neuroradiology; Medicine/Public Health, general
- ISSN
- 0300-9009
- eISSN
- 2240-2993
- DOI
- 10.1007/s13760-017-0794-7
- pmid
- 28528469
- Publisher site
- See Article on Publisher Site
Abstract
Fingolimod was the first oral medication approved for management of multiple sclerosis and is currently used by tens of thousands patients worldwide. Fingolimod acts via the sphingosine 1-phosphate (S1P) receptor, maintaining peripheral lymphocytes entrapped in the lymph nodes. In consequence, there is a reduction in the infiltration of aggressive lymphocytes into the central nervous system. The drug is safe and effective, and its first hours of use are associated with related to S1P receptors in the heart. This side effect is well known by all doctors prescribing fingolimod. However, the drug has other potential adverse events that, although relatively rare, require awareness from the neurologist. Among these there are infections (herpes simplex, herpes zoster, Cryptococcus, Epstein–Barr virus, hepatitis, Molluscum Contagiosum, and leishmaniosis), lung and thyroid complications, refractory headaches, encephalopathy, vasculopathy, tumefactive lesions in magnetic resonance imaging and ophthalmological disorders. The present review lists the non-cardiologic adverse events that all neurologists prescribing fingolimod should be aware of.
Journal
Acta Neurologica Belgica – Springer Journals
Published: May 20, 2017